Cite
HARVARD Citation
Furr Stimming, E. et al. (n.d.). J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington's disease (HD). Journal of neurology, neurosurgery and psychiatry. p. A95. [Online].